5 European Projects Found
Searched on 125080 European Projects
FINISHED
Targeting novel lipid pathways for treatment of cardiovascular disease (Athero-Flux)
Start date: Sep 1, 2013, End date: Aug 31, 2018,
Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct cer ...
Read Project
12
Partners Participants
FINISHED
Micropattern-Enhanced High Throughput RNA Interference for Cell Screening (MEHTRICS)
Start date: Oct 1, 2011, End date: Jan 31, 2015,
...ce for all major applications of HT/HC cell screening. The resulting new tools and methodologies will be incorporated into the commercial offerings of the consortium’s two key SMEs, CYTOO and CENIX.
Read Project
6
Partners Participants
FINISHED
Targeted Amphoteric Carriers in ImmunoTherapy (TACIT)
Start date: Aug 1, 2009, End date: Jul 31, 2013,
"The past year has been exciting for oligonucleotide-based drug discovery and development. The Nobel Prize was awarded to Mello and Fire for discovering RNA interference. There was also big investment from the Pharmaceutical industry to Biotechnology companies-pioneers in oligonucleotide therapeutics such as Sirna, Alnylam and Isis, all US-based. High expectations were therefore raised but further ...
Read Project
4
Partners Participants
FINISHED
Multi-layer network modules to identify markers for personalized medication in complex diseases (MultiMod)
Start date: Nov 1, 2008, End date: Oct 31, 2012,
The symptoms of complex disease like allergy, obesity and cancer depend on the products of multiple interacting genes. High-throughput techniques have implicated hundreds of genes. There are also considerable individual variations. A clinical implication of this may be inadequate treatment response, which is increasingly recognized as a cause of increased suffering and costs. Ideally, physicians s ...
Read Project
6
Partners Participants
FINISHED
An urgent need exists for more specific treatment options to target the metabolic changes and the related inflammatory pathways during HF. Targeting microRNAs (miRNAs)-small RNAs implicated in protein regulation- represents a unique possibility to make novel medicines against HF. In view of the central role of inflammatory pathways in the metabolic syndrome, they expect inflammation miRNAs to be e ...
Read Project
